Advanced Biomedical Technologies Stock

Advanced Biomedical Technologies EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Advanced Biomedical Technologies (ABMT) as of Aug 5, 2026 is -0.02. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.02 — a change of 35.40% (lower).

EV/EBIT

-0.02

YoY

35.40%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Advanced Biomedical Technologies is 2026 -0.02 . EV/EBIT (Enterprise Value to EBIT) of Advanced Biomedical Technologies was 2025 -0.02 . It decreases by 35.40% lower compared to the previous year.

The Advanced Biomedical Technologies EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2013
0.00 base
Jan 1, 2014
0.00 base
Jan 1, 2015
0.00 base
Jan 1, 2016
0.00 base
Jan 1, 2017
0.00 base
Jan 1, 2018
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
YEARPRICE-TO-EBIT
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
Access this data via the Eulerpool API
Get Free API Key

Advanced Biomedical Technologies Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Advanced Biomedical Technologies's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Advanced Biomedical Technologies's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Advanced Biomedical Technologies's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Advanced Biomedical Technologies grows earnings faster than its peers.

Advanced Biomedical Technologies Stock analysis

What does Advanced Biomedical Technologies do? Advanced Biomedical Technologies Inc is an innovative biomedical company specializing in the development of advanced medical devices and technologies. The company was founded in 1985 by an experienced team of biotech experts and is headquartered in California, USA. History: The company's roots lie in the research and development of novel medical implants and prosthetics. However, over the years, the company has quickly evolved into a leading provider of medical devices and technologies in the fields of diagnostics, therapy, and care. Business model: The business model of Advanced Biomedical Technologies Inc is focused on providing innovative and advanced solutions for medical care. The company strives to continuously develop its products and help customers achieve their healthcare goals. Divisions: The company is divided into four main divisions focusing on different medical areas: 1) Interventional Cardiology: Here, the company develops devices for the treatment of heart diseases, such as stents for reopening narrowed vessels. 2) Orthopedics: Another focus is on the development of innovative orthopedic implants and prosthetics that help patients regain their mobility and improve their quality of life. 3) Oncology: In this division, the company works on the development of medical devices and systems for the diagnosis and treatment of cancer. 4) Neurology: Here, the company focuses on the development of medical technologies and devices for the diagnosis and treatment of nervous system disorders, such as Parkinson's or Alzheimer's. Products: Advanced Biomedical Technologies Inc's products include a variety of medical devices and technologies specialized in different medical areas. Some of the company's most well-known products are: - Stents for reopening narrowed vessels in the heart - Artificial joints and implants for restoring mobility and quality of life - Medical devices for the diagnosis and treatment of cancer - Neurostimulation devices for the treatment of chronic pain and other neurological disorders - Robot-assisted surgery systems that assist surgeons in complex procedures. Conclusion: Advanced Biomedical Technologies Inc is a leading biomedical company specializing in the development of advanced medical devices and technologies. The company has a long history in the research and development of medical implants and prosthetics but has quickly expanded into a broader range of medical applications. With its focus on developing innovative products for patients' quality of life, Advanced Biomedical Technologies Inc will continue to play an important role in medical innovation. Advanced Biomedical Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Advanced Biomedical Technologies stock

EV/EBIT (Enterprise Value to EBIT) of Advanced Biomedical Technologies is -0.02 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Advanced Biomedical Technologies changed from -0.02 to -0.02, representing a 35.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Advanced Biomedical Technologies since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Advanced Biomedical Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Advanced Biomedical Technologies

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Advanced Biomedical Technologies